Myriad Agrees To Acquire Javelin In Stock-Swap Transaction
This article was originally published in The Pink Sheet Daily
Executive Summary
The Myriad Genetics spinout is hastening its progress into a commercial company by buying Javelin, although investors are grumbling about the deal terms.